GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Solara Active Pharma Sciences SOLARA.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

648.05

+2.26%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹13.69bn

FY2017FY2026

Net income

−₹74.1m

FY2017FY2026

Free cash flow

₹88.8m

FY2017FY2026

Shareholders' equity

₹12.53bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹13.69bn₹12.84bn₹12.89bn₹14.27bn₹12.68bn₹15.97bn₹12.68bn₹13.22bn₹5.21bn₹9.41bn
Research and development—₹344.8m₹559.8m₹461.6m₹656.2m₹529.1m₹585.7m₹440.5m₹18.2m—
Operating income₹870.7m₹1.15bn−₹3.83bn₹85.6m−₹259.9m₹2.62bn₹1.73bn₹1.50bn₹289.8m₹584.4m
Net income−₹74.1m₹5.4m−₹5.67bn−₹221.7m−₹581.5m₹2.21bn₹1.15bn₹595.3m₹3.8m₹301.6m
Diluted earnings per share-1.600.12-142.37-6.16-16.1561.6230.1221.930.1510.22

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹23.33bn₹22.32bn₹23.51bn₹28.99bn₹29.53bn₹26.14bn₹21.54bn₹19.60bn₹18.22bn₹100,000
Cash and short-term investments₹533.4m₹41.1m₹84.4m₹87.3m₹463.8m₹1.98bn₹560.4m₹757.2m₹459.5m₹100,000
Total liabilities₹10.77bn₹11.35bn₹14.14bn₹13.97bn₹14.18bn₹10.21bn₹10.63bn₹10.00bn₹10.53bn₹33,000
Debt₹6.87bn₹7.96bn₹10.12bn₹10.13bn₹10.37bn₹6.21bn₹7.22bn₹5.38bn₹6.33bn—
Shareholders' equity₹12.53bn₹10.94bn₹9.34bn₹15.00bn₹15.25bn₹15.89bn₹10.86bn₹9.56bn₹7.64bn₹67,000
Shares outstanding46m44m40m36m36m36m38m27m25m30m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations₹617.0m₹2.13bn₹1.09bn₹1.56bn−₹2.42bn₹1.55bn₹2.44bn₹1.60bn₹492.2m₹492.2m
Capital spending−₹528.2m−₹399.4m−₹410.6m−₹1.11bn−₹2.09bn−₹1.74bn−₹2.69bn−₹525.4m−₹347.4m−₹347.4m
Free cash flow₹88.8m₹1.73bn₹678.1m₹449.4m−₹4.51bn−₹190.2m−₹246.5m₹1.07bn₹144.9m₹144.9m
Dividends paid————−₹107.8m−₹197.3m−₹128.9m−₹128.9m−₹156.2m−₹128.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹3.82bn₹3.87bn₹3.49bn₹3.14bn₹3.19bn₹2.73bn₹3.00bn₹3.47bn
Operating income₹352.6m₹316.2m₹117.7m₹102.4m₹334.4m₹210.7m₹346.3m₹362.9m
Net income₹163.1m₹96.0m−₹174.3m−₹101.0m₹105.2m−₹21.0m₹80.9m₹80.1m
Diluted earnings per share3.522.07-3.92-2.272.36-0.472.032.01
Cash from operations———₹740.0m—₹2.13bn—₹998.0m
Capital spending———−₹286.0m—−₹399.0m—−₹197.0m
Free cash flow———₹454.0m—₹1.73bn—₹801.0m
Total assets—₹23.33bn—₹22.93bn—₹22.32bn—₹22.90bn
Cash and short-term investments₹533.4m₹533.4m₹38.7m₹169.3m₹41.1m₹41.1m₹60.7m₹60.7m
Debt—₹6.67bn—₹6.46bn—₹7.96bn—₹8.40bn
Shareholders' equity₹12.56bn₹12.53bn₹12.57bn₹12.55bn₹10.97bn₹10.94bn₹10.89bn₹10.86bn

Financial ratios

Data as of 25 Sept 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin6.4%9.0%-29.7%0.6%-2.0%16.4%—
Net margin-0.5%0.0%-44.0%-1.6%-4.6%13.9%—
Return on equity-0.6%0.0%-60.8%-1.5%-3.8%13.9%—
Return on assets-0.3%0.0%-24.1%-0.8%-2.0%8.5%—
Free cash flow yield3.4%7.7%5.1%10.1%-1.3%12.5%—
Revenue growth6.6%-0.4%-9.7%12.5%-20.6%26.0%—
Earnings growth-1472.2%-100.1%2459.3%-61.9%-126.3%93.2%—
Current ratio0.96x0.77x0.64x1.08x1.17x1.34x—
Debt to equity0.53x0.71x1.07x0.67x0.67x0.38x—
Equity ratio53.7%49.0%39.7%51.7%51.6%60.8%—
Interest coverage0.92x1.00x-3.70x0.10x-0.37x3.10x—
R&D as a share of sales—2.7%4.3%3.2%5.2%3.3%4.6%
Buybacks as a share of market value-4.1%-11.6%-10.7%0.0%-0.2%5.6%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.4%-3.0%—
Operating income116.7%-19.8%—
Net income-30.6%——

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-406.2—-4.8-58.6-26.616.539.619.8—
Price to sales2.22.02.10.91.22.33.60.91.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 18 Aug 2021.

FY2022FY2021FY2020
Paid in the year3.006.005.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.